YELLOWSkin / Anti-Inflammatory

KLOW Blend

KLOW Blend (GHK-Cu / KPV / BPC-157 / TB500)

Research compound1 SKU available
GHK-CuGHK-Cu
KPVKPV
BPC-157BPC-157
TB500TB500

Blend components — PubChem

Research Hub — Aggregated Studies

MedTech Research Group aggregates published research from peer-reviewed journals, clinical trials, and academic institutions. We do not conduct original research. All studies cited below are the work of their respective authors and institutions. Sources are linked for verification.

This product is designated FOR RESEARCH USE ONLY (RUO). These compounds have not been approved or cleared under 21 U.S.C. § 505 and have not been evaluated by the FDA for safety, efficacy, or labeling for clinical, diagnostic, or therapeutic use in humans or animals.

MedTech Research Group will only fulfill orders to qualified researchers affiliated with accredited academic institutions, licensed research facilities, or organizations with active IRB/IACUC oversight.

Purchaser Restrictions

  • Purchaser must be a qualified researcher at an accredited institution or licensed research facility
  • This product may not be sold or redistributed to individual consumers, wellness clinics, health food stores, or retail establishments
  • Not intended for human or animal consumption, diagnostic use, or therapeutic application
  • Institutional affiliation and research purpose will be verified prior to order fulfillment

Distribution is limited to qualified research use in compliance with applicable federal and state law. These products bear the "For Research Use Only" designation per FDA labeling requirements (minimum 10 pt. font). Ref: 21 U.S.C. § 505; FD&C Act § 201(p) (unapproved new drug definition).

Compound Overview
Risk TierYELLOW
CategorySkin / Anti-Inflammatory
SubcategoryMulti-Peptide Skin Repair with Anti-Inflammatory Focus
Pharmacological ClassCombination Peptide
SubclassCopper Peptide + Anti-Inflammatory Tripeptide + Cytoprotective + Actin-Sequestering Blend
Molecular TypeFour-peptide lyophilized combination
OriginAll synthetic components
Regulatory StatusResearch Use Only
Route of AdministrationSubcutaneous injection
ReconstitutionLyophilized powder; reconstitute with bacteriostatic water
StorageRefrigerate (2-8°C)
Detailed Research

Description

The KLOW Blend is an enhanced version of the GLOW Blend with the addition of KPV (Lys-Pro-Val), a potent anti-inflammatory tripeptide. While the GLOW Blend targets skin rejuvenation through collagen stimulation, tissue repair, and cell migration, the KLOW Blend adds a dedicated anti-inflammatory component that specifically targets NFkB-mediated inflammatory pathways in the skin.

The addition of KPV makes the KLOW Blend more suitable for research involving inflammatory skin conditions — situations where the skin's healing capacity is compromised by chronic inflammation. KPV (derived from alpha-melanocyte stimulating hormone) is one of the most potent naturally-derived anti-inflammatory peptides known, with demonstrated efficacy in inflammatory bowel disease and dermatitis models. By suppressing the inflammatory milieu, KPV may create a more favorable environment for the regenerative effects of GHK-Cu, BPC-157, and TB500 to take effect.

Clinical Context

The KLOW Blend builds on the GLOW formulation by adding KPV, a dedicated anti-inflammatory tripeptide derived from alpha-melanocyte stimulating hormone. This makes it more targeted for research involving inflammatory skin conditions where chronic inflammation impairs healing. The four-peptide combination provides 29% cost savings compared to purchasing components separately, while adding the anti-inflammatory dimension that the GLOW Blend lacks.

Research Applications
Inflammatory skin condition research (dermatitis, rosacea, psoriasis models)
Post-inflammatory hyperpigmentation
Acne scarring and inflammatory acne
Skin barrier repair in inflammatory contexts
Chronic wound healing with inflammatory component
Comparative studies vs. GLOW Blend
Clinician Notes
Important Notes for Clinicians
  • All individual component warnings apply (see GHK-Cu, KPV, BPC-157, TB500 sections)
  • The four-peptide formulation increases complexity and potential for peptide-peptide interactions
  • Cost analysis: separate components would cost approximately $134.35 vs. $95.78 for the blend — a 29% cost savings

Published Research

Published Research & Clinical Data

Peer-reviewed studies and clinical trial data related to KLOW Blend

All research below is conducted by independent institutions. MedTech Research Group provides these references for informational purposes only.

Research citations are being compiled for this compound.

Check back soon — our team is curating peer-reviewed sources.